#None #Companion Diagnostics #Waters Corporation #CellCarta

CellCarta and Waters: Pioneering Companion Diagnostics

In a significant move to enhance the development of companion diagnostics, CellCarta, a prominent global contract research organization (CRO) in the biopharmaceutical sector, has announced a strategic partnership with the Waters Corporation, a leader in life sciences and diagnostic solutions. This collaboration is set to revolutionize how pharmaceutical and biotechnology companies navigate the complexities of developing diagnostic tests that complement therapeutic treatments.

A New Era for Companion Diagnostics

The collaboration between CellCarta and Waters aims to create a comprehensive framework to pursue opportunities related to companion diagnostics (CDx) and next-generation flow cytometry. Initial efforts will focus on flow cytometry-based programs, an area in which both organizations excel. This strategic partnership seeks to equip sponsors with a streamlined route from biomarker strategy formulation through to clinical development, regulatory approval, and eventually, commercialization on a global scale.

CellCarta brings its vast expertise in biomarker research and clinical trial testing to the table, while Waters contributes advanced technology, including state-of-the-art equipment, reagents, and assay development capabilities. The combination of these two powerhouses is expected to yield a more connected and efficient path for drug sponsors, enhancing their ability to integrate diagnostics and therapeutics seamlessly.

Collaborative Expertise

The strengths of CellCarta and Waters are complementary, spanning numerous critical areas of assay innovation. Waters provides cutting-edge instrumentation and reagents, alongside standardized panels that can accelerate the development process. In contrast, CellCarta leverages its extensive knowledge in translational research and regulatory logistics to deploy assays effectively across its global CDx Lab Network.

Together, they intend to deliver standardized, scalable solutions that cater to the growing demand for precision medicine. Todd Chermak, President of CellCarta, highlights that the partnership represents a clear business value for biopharmaceutical sponsors by mitigating complexity and enhancing program continuity.

A Focus on Global Collaboration

Particularly notable is the alignment between CellCarta's highly accredited laboratory capabilities in Jining, China, and Waters' flow cytometry platforms. The partnership is strategically positioned to facilitate multinational CDx programs, especially for sponsors looking to incorporate China into their therapeutic strategies and diagnostic approaches. This cooperative effort not only supports existing biopharmaceutical firms but also paves the way for China-based companies targeting the global market.

Christopher Ung, Chief Scientific Business Officer for CellCarta, remarked on the partnership's ability to create coherent strategies that address both local and international regulatory landscapes. The collaboration aims to link patient selection processes with treatment-response assessments, ensuring that China is integrated into the overall strategy from the outset.

Innovations in Flow Cytometry

The advancements in next-generation flow cytometry are opening new avenues for laboratories to enhance their analytical capabilities. This technology allows for a more detailed examination of rare cells, driving greater consistency across all operational workflows. By merging CellCarta's vast contract research organization experience with Waters' proficiency in clinical assay development, the partnership aims to transform cellular insights into clinical assays that can be reliably applied across various programs and regions.

About the Companies

CellCarta stands as a leader in the CRO landscape, having earned CAP accreditation and CLIA certifications across facilities in multiple countries, including Canada, the USA, Belgium, Australia, and China. The organization provides a wide range of biomarker testing and customized solutions to renowned pharmaceutical firms, supporting every stage of the drug development lifecycle from discovery to late-stage clinical trials.

For those interested in learning more about CellCarta and its innovative partnerships, detailed information can be found on their website and they can be followed on LinkedIn for updates on their latest advancements in the biopharmaceutical industry.

As the landscape of companion diagnostics continues to evolve, this partnership between CellCarta and Waters stands as a testament to the innovative potential of combining expertise in clinical and diagnostic development, paving the way for breakthroughs in patient care and treatment efficacy.